Mol. Cells 2013; 36(2): 177-184
Published online July 4, 2013
https://doi.org/10.1007/s10059-013-0061-6
© The Korean Society for Molecular and Cellular Biology
It has been suggested that activation of receptor PTKs is important for leukemogenesis and leukemia cell response to targeted therapy in hematological malignancies including leukemia. PTKs induce activation of the PI3K/Akt/mTOR pathway, which can result in prevention of apoptosis. Here, we describe an important role of the TrkC-associated molecular network in the process of leukemogenesis. TrkC was found to be frequently overexpressed in human leukemia cells and leukemia subtypes. In U937 human leukemia cells, blockade of TrkC using small hairpin RNA (shRNA) specific to TrkC or K562a, a specific inhibitor of TrkC, resulted in a significant decrease in growth and survival of the cells, which was closely associated with reduced mTOR level and Akt activity. In addition, TrkC enhances the survival and proliferation of leukemia, which is correlated with activation of the PI3K/Akt pathway. Moreover, TrkC significantly inhibits apoptosis via induction of the expression of PLK-1 and Twist-1 through activation of AKT/mTor pathway; therefore, it plays a key role in leukemogenesis. These findings reveal an unexpected physiological role for TrkC in the pathogenesis of leukemia and have important implications for understanding various hematological malignancies.
Keywords apoptosis, hematological malignancies, PI3K/Akt/Mtor, survival and growth, TrkC
Mol. Cells 2013; 36(2): 177-184
Published online August 31, 2013 https://doi.org/10.1007/s10059-013-0061-6
Copyright © The Korean Society for Molecular and Cellular Biology.
Min Soo Kim, Gyoung Mi Kim, Yun-Jeong Choi, Hye Joung Kim2, Yoo-Jin, Kim, and Wook Jin
1Department of Molecular Medicine, School of Medicine, Gachon University, Incheon 406-840, Korea, 2Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea, 3Gachon Medical Research Institute, Gil Medical Center, Incheon 405-760, Korea, 4These authors contributed equally to this work.
It has been suggested that activation of receptor PTKs is important for leukemogenesis and leukemia cell response to targeted therapy in hematological malignancies including leukemia. PTKs induce activation of the PI3K/Akt/mTOR pathway, which can result in prevention of apoptosis. Here, we describe an important role of the TrkC-associated molecular network in the process of leukemogenesis. TrkC was found to be frequently overexpressed in human leukemia cells and leukemia subtypes. In U937 human leukemia cells, blockade of TrkC using small hairpin RNA (shRNA) specific to TrkC or K562a, a specific inhibitor of TrkC, resulted in a significant decrease in growth and survival of the cells, which was closely associated with reduced mTOR level and Akt activity. In addition, TrkC enhances the survival and proliferation of leukemia, which is correlated with activation of the PI3K/Akt pathway. Moreover, TrkC significantly inhibits apoptosis via induction of the expression of PLK-1 and Twist-1 through activation of AKT/mTor pathway; therefore, it plays a key role in leukemogenesis. These findings reveal an unexpected physiological role for TrkC in the pathogenesis of leukemia and have important implications for understanding various hematological malignancies.
Keywords: apoptosis, hematological malignancies, PI3K/Akt/Mtor, survival and growth, TrkC
Soo-Jin Lee, Sung-E Choi, Seokho Park, Yoonjung Hwang, Youngho Son, and Yup Kang*
Mol. Cells 2023; 46(8): 496-512 https://doi.org/10.14348/molcells.2023.0045Juyong Kim, Sangwoo Seo, Jung Han Yoon Park, Ki Won Lee, Jiyoung Kim, and Jin-Chul Kim
Mol. Cells 2023; 46(5): 319-328 https://doi.org/10.14348/molcells.2023.2156Kwangho Kim, Tae Young Ryu, Jinkwon Lee, Mi-Young Son, Dae-Soo Kim, Sang Kyum Kim, and Hyun-Soo Cho
Mol. Cells 2022; 45(9): 622-630 https://doi.org/10.14348/molcells.2022.0014